Eli Lilly widens obesity drug lead as Zepbound, Mounjaro sales soar

Sales of Zepbound and Mounjaro soared during the second quarter, easily beating Wall Street estimates and widening the gap ...

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street ...

Eli Lilly Q2 Earnings Review: Breath-Taking Results Mean Higher Ceiling On Stock Price Target

Eli Lilly and Company beats earnings, boosts 2026 guidance on GLP-1 drugs Mounjaro/Zepbound. Click here to read my most ...
24/7 Wall St.

GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future

Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may ...

Why Eli Lilly Stock Climbed Today

Shares of Eli Lilly (NYSE: LLY) rose on Wednesday after the medicine maker highlighted the booming sales of its popular ...

Eli Lilly jumps after Q2 beat driven by obesity drugs

Eli Lilly (LLY) stock jumps as the firm posts better-than-expected Q2 2026 results, driven by its injectable GLP-1s and its ...

Eli Lilly CEO David Ricks on Q2 results: We're pleased but not satisfied

David Ricks, Eli Lilly chairman and CEO, joins 'Squawk Box' to discuss second-quarter earnings and revenue that easily beat ...